Shockwave Prepares For FDA Approval Of Coronary Intravascular Lithotripsy System

The company expects the FDA to approve its intravascular lithotripsy system with the C2 coronary catheter in early 2021 based on results from the Disrupt CAD III study.

• Source: Shockwave Medical (Scott Shadiow)

Shockwave Medical, Inc. is preparing to launch its coronary intravascular lithotripsy system in the US in early 2021, supported by a US field team of over 100 people.

Shockwave’s lithotripsy technology combines an angioplasty balloon catheter with sonic pressure wave emitters to disrupt heavily calcified vascular plaques. The...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Approvals

More from Policy & Regulation